Clinical trial · Observational
Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA)
Coronavirus Outcomes Registries in Immunocompromised Individuals Australia (CORIA): a Multisite Registry and Optional Biorepository in People With COVID-19 and Selected Conditions Affecting Immune Function
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
CORIA is an observational cohort study of immunosuppressed populations who test positive for COVID-19. This includes people living with HIV, cancer, acquired immunodeficiency associated with other immunosuppressive therapy, primary immunodeficiency and recipients of a solid organ transplant. Participants will have routine clinical data collected with optional baseline collection and storage of a blood sample for storage . The study will be conducted in up to 30 sites within Australia.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| COVID-19 | — | UNRESOLVED | — |
| HIV-1-infection | — | UNRESOLVED | — |
| Immunosuppression Disorders | — | UNRESOLVED | — |
| Primary Immune Deficiency Disorder | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (5)
- label
- People living with HIV
- label
- Recipients of Solid Organ Transplants
- label
- People Living with Cancer
- label
- People with acquired immunodeficiency
- description
- Patients with acquired immunodeficiency associated with other immunosuppressive therapy.
- label
- People with primary immunodeficiency
Primary outcomes (1)
- measure
- percentage of patients who required hospitalisation, developed severe illness (ICU admission) or died
- timeFrame
- Day 28
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Presenting (in person or via telemedicine) for evaluation because they: * Have clinical symptoms consistent with for COVID-19: * Fever (≥ 37.8 °C) on examination OR patient reported fever (≥ 37.8 °C) or feverishness (felt febrile but did not take temperature) OR any of, cough, sore throat, shortness of breath, rhinorrhoea, headache, chills, generalise myalgia, malaise, fatigue, confusion, diarrhea, nausea or vomiting * Have been contacted because they have been identified as a contact to a confirmed case * Have been contacted and told they tested positive for COVID-19 2. Have one of the following conditions affecting immune function: * Known or suspected primary immunodeficiency, defined as a predisposition to infection associated with an apparent or presumed deficit of immune function * On immunosuppressive therapy * Treatment with immune checkpoint inhibitors within 36 months of enrolment date * HIV infection * Diagnosis of cancer within 36 months of enrolment date, excluding superficial basal cell and squamous cell carcinomas * Solid organ transplantation 3. For optional biobanking only, ability to provide informed consent Exclusion Criteria: * Nil
References
Publications (0)
Data not yet available